Number of the records: 1
Cotargeting of BCL2 with Venetoclax and MCL1 with S63845 Is Synthetically Lethal In Vivo in Relapsed Mantle Cell Lymphoma
- 1.
SYSNO ASEP 0521329 Document Type J - Journal Article R&D Document Type Journal Article Subsidiary J Článek ve WOS Title Cotargeting of BCL2 with Venetoclax and MCL1 with S63845 Is Synthetically Lethal In Vivo in Relapsed Mantle Cell Lymphoma Author(s) Průková, D. (CZ)
Anděra, Ladislav (BTO-N)
Nahácka, Zuzana (BTO-N)
Karolová, J. (CZ)
Svaton, M. (CZ)
Klanova, M. (CZ)
Havranek, O. (CZ)
Soukup, J. (CZ)
Svobodová, K. (CZ)
Zemanová, Z. (CZ)
Tušková, D. (CZ)
Pokorná, E. (CZ)
Helman, K. (CZ)
Forsterova, K. (CZ)
Pacheco-Blanco, M. (CZ)
Vockova, P. (CZ)
Berková, A. (CZ)
Froňková, E. (CZ)
Trněný, M. (CZ)
Klener, P. (CZ)Number of authors 20 Source Title Clinical Cancer Research. - : American Association for Cancer Research - ISSN 1078-0432
Roč. 25, č. 14 (2019), s. 4455-4465Number of pages 11 s. Language eng - English Country US - United States Keywords acute myeloid-leukemia ; open-label ; cancer ; landscape Subject RIV FD - Oncology ; Hematology OECD category Oncology Method of publishing Open access Institutional support BTO-N - RVO:86652036 UT WOS 000478018100027 DOI 10.1158/1078-0432.CCR-18-3275 Annotation Purpose: Mantle cell lymphoma (MCL) is an aggressive subtype of B-cell non-Hodgkin lymphomas characterized by (over) expression of BCL2. A BCL2-targeting drug, venetoclax, has promising anticancer activity in MCL. We analyzed molecular mechanisms of venetoclax resistance in MCL cells and tested strategies to overcome it. Workplace Institute of Biotechnology Contact Monika Kopřivová, Monika.Koprivova@ibt.cas.cz, Tel.: 325 873 700 Year of Publishing 2020 Electronic address https://clincancerres.aacrjournals.org/content/25/14/4455
Number of the records: 1